Annual Cash & Cash Equivalents
$145.65 M
+$22.09 M+17.88%
December 31, 2023
Summary
- As of February 26, 2025, LYEL annual cash & cash equivalents is $145.65 million, with the most recent change of +$22.09 million (+17.88%) on December 31, 2023.
- During the last 3 years, LYEL annual cash & cash equivalents has risen by +$5.24 million (+3.73%).
- LYEL annual cash & cash equivalents is now -50.43% below its all-time high of $293.83 million, reached on December 31, 2021.
Performance
LYEL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$100.30 M
-$33.13 M-24.83%
September 30, 2024
Summary
- As of February 26, 2025, LYEL quarterly cash and cash equivalents is $100.30 million, with the most recent change of -$33.13 million (-24.83%) on September 30, 2024.
- Over the past year, LYEL quarterly cash and cash equivalents has dropped by -$45.35 million (-31.14%).
- LYEL quarterly cash and cash equivalents is now -82.23% below its all-time high of $564.44 million, reached on June 30, 2021.
Performance
LYEL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
LYEL Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +17.9% | -31.1% |
3 y3 years | +3.7% | -65.9% |
5 y5 years | +50.7% | -82.2% |
LYEL Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -50.4% | +17.9% | -65.9% | at low |
5 y | 5-year | -50.4% | +50.7% | -82.2% | at low |
alltime | all time | -50.4% | +50.7% | -82.2% | at low |
Lyell Immunopharma Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $100.30 M(-24.8%) |
Jun 2024 | - | $133.42 M(+6.2%) |
Mar 2024 | - | $125.65 M(-13.7%) |
Dec 2023 | $145.65 M(+17.9%) | $145.65 M(-49.1%) |
Sep 2023 | - | $286.21 M(+27.6%) |
Jun 2023 | - | $224.37 M(+105.0%) |
Mar 2023 | - | $109.43 M(-11.4%) |
Dec 2022 | $123.55 M | $123.55 M(+6.2%) |
Sep 2022 | - | $116.31 M(-43.5%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2022 | - | $205.74 M(-7.6%) |
Mar 2022 | - | $222.60 M(-24.2%) |
Dec 2021 | $293.83 M(+109.3%) | $293.83 M(-25.3%) |
Sep 2021 | - | $393.50 M(-30.3%) |
Jun 2021 | - | $564.44 M(+131.0%) |
Mar 2021 | - | $244.37 M(+74.0%) |
Dec 2020 | $140.41 M(+45.2%) | - |
Dec 2020 | - | $140.41 M |
Dec 2019 | $96.67 M | - |
FAQ
- What is Lyell Immunopharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lyell Immunopharma?
- What is Lyell Immunopharma annual cash & cash equivalents year-on-year change?
- What is Lyell Immunopharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lyell Immunopharma?
- What is Lyell Immunopharma quarterly cash and cash equivalents year-on-year change?
What is Lyell Immunopharma annual cash & cash equivalents?
The current annual cash & cash equivalents of LYEL is $145.65 M
What is the all time high annual cash & cash equivalents for Lyell Immunopharma?
Lyell Immunopharma all-time high annual cash & cash equivalents is $293.83 M
What is Lyell Immunopharma annual cash & cash equivalents year-on-year change?
Over the past year, LYEL annual cash & cash equivalents has changed by +$22.09 M (+17.88%)
What is Lyell Immunopharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LYEL is $100.30 M
What is the all time high quarterly cash and cash equivalents for Lyell Immunopharma?
Lyell Immunopharma all-time high quarterly cash and cash equivalents is $564.44 M
What is Lyell Immunopharma quarterly cash and cash equivalents year-on-year change?
Over the past year, LYEL quarterly cash and cash equivalents has changed by -$45.35 M (-31.14%)